The Effects Of Erythropoietin On Liver Tissue In An Experimental Rat Model Of Septic Shock

Öz

Background: Sepsis is a systemic response that develops
against infection and inflammation. These disorders remain the most important cause of mortality in intensive
care units.
Materal-Methods: In the present study, we used an experimental model of sepsis and septic shock by cecal ligation and perforation in rats to investigate the effects
of erythropoetin on hepatic functions and liver histology.
Findings: After treatment, we found statistically significant improvement in AST and ALT values at Erythropoietin treatment group. Also statistically significant improvements were observed in histological findings of liver
in rats treated with erythropoetin.
Results: In this study, we used erythropoietin to treat
the septic shock and ischemia-perfusion injury and inflammation. Data suggest that erythropoetin for the treatment of septic shock, as well as the liver damage resulting from the septic shock. Results of this study should
prompt future clinical studies. It seems likely that erythropoetin protects the organs against sepsis-induced oxidative organ injury.

Anahtar Kelimeler

• erythropoetin
• sepsis
• rat
• liver

Deneysel Septik Şok Modeli Oluşturulan Ratlarda Eritropoetinin Karaciğer Dokusu Üzerine Etkisi

Öz

Giriş: Sepsis, inflamasyon ve enfeksiyon tablolarına karşı verilen sistemik bir yanıttır. Yoğun bakım ünitelerindeki en önemli ölüm sebeplerindendir.

Materyal-Metot: Bu çalışmada ratlarda çekal ligasyon ve perforasyon modeli ile oluşturulan deneysel septik şok modeli kullanarak eritropoetinin hepatik fonksiyonlar ve histolojik bulguları üzerindeki etkilerini araştırdık.

Bulgular: Eritropoetin uygulanan tedavi grubuna ait sı- çanlarda tedavi sonrası AST ve ALT değerlerinde istatistiksel olarak anlamlı düzelme saptadık. Ayrıca eritropoietin ile tedavi edilen sıçanlardan karaciğerin histolojik yapı- sında istatistiksel olarak anlamlı düzelme saptadık.

Sonuç: Bu çalışmada septik şoktaki iskemi-perfüzyon hasarı ve inflamasyon tedavisinde eritropoetin kullandık. Veriler, septik şokun tedavisinde ve septik şoktan kaynaklanan karaciğer hasarında eritropoetin kullanımını önermektedir. Bu çalışmanın sonuçları, gelecekteki klinik çalışmaları teşvik edecektir. Eritropoetin, sepsis kaynaklı oksidatif hasardan organları korur gibi görünmektedir

Anahtar Kelimeler

• Eritropoetin
• sepsis
• fare
• karaciğer

Kaynakça

1. Alberti C, Brun-Buisson C, Burchardi H, et al. Epidemiology of sepsis and infection in ICU pa- tients from an international multicentre cohort study. Intensive Care Med. 2002; 28: 108-21.
2. Matot I, Sprung CL. Definition of sepsis. In- tensive Care Med. 2001; 27: 3-9.
3. Hines DW, Bone RC. Septic Shock. In: Gorba- ch SL, Bartlett JG, Blacklow NR(eds). Infectious Diseases. Second Edition. W.B. Saunders Co., Philadelphia, 1992; 544-48.
4. Krantz SB. Erythropoietin. Blood 1991; 77: transplantation 2007; 4: 16-17. 419
5. Sepodes B, Maio R, Pinto R, Sharples E, Oli- Woodman D.D.: Erythropoetin, Comparative Haematology International; 1992; 2: 1-7.
6. Fisher J.W. Erytropoietin, In Massry S.G., Glas- sock R.J., Textbook of Nephrology, 3rd Edition, Williams & Wilkins, Baltimore, Maryland USA, 1995; 191- 197.
7. Ghezi P, Brines M. Erythropoietin as an antia- poptotic, tissue-protective cytokine. Cell Death and Differentiation 2004; 11: 37–44.
8. BakerJE. Erythropoietin mimics ischemic pre- conditioning. Pharmacology and Toxicology, Biochemistry and Pediatric Surgery, Medical College of Wisconsin, 8701 Watertown Plank

9. Road, Milwaukee, WI 53226, USA. 2005; 42 (5-6): 233
10. Villa P, Sartor G, Angelini M, et al. Pattern of cytokines and pharmacomodulation in sepsis induced by cecal ligation and puncture compa- red with that induced by endotoxin. Clin Diagn Lab Immunol 1995; 2: 549-553.
11. Pascual J, Teruel JL, Moya JL, Liaño F, Jimé- nez-Mena M, Ortuño J. Regression of left vent- ricular hypertrophy after partial correction of anemia with erythropoietin in patients on he- modialysis: a prospective study. Clin Nephrol. zi R, Patel N, Thiemermann C. Pharmacological 2008;280-7. preconditioning with erythropoietin attenua
12. Maiese K, Li F, Chong ZZ. New avenues of exploration for erythropoietin. JAMA. 2005; 293: 90-95.
13. Vedat Bakan, Harun Çıralık, Fatma Inanaç dels & Mechanisms 2013; (6): 701-709.